Developing new drugs and vaccines for cancer treatment
Official title: Contract Orientation and Kickoff Meeting
Funded at University of Oklahoma Hlth Sciences Ctr · NIH-11020354 · Data updated 2026-11-12
This study is working on creating new medicines and vaccines to help treat different kinds of cancer, and it's designed to find out what works best for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project start | January 25, 2024 |
| Project end | January 24, 2029 |
| Funding year | 2024 |
| Award (this year) | $3,500 |
| NIH project number | 75N91024D00005-0-759102400001-1 |
| Project ID | NIH-11020354 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with various types of cancer who may benefit from new therapeutic options.
✕Less likely to help
Patients with non-malignant conditions or those who are not currently diagnosed with cancer may not receive any benefit from this research.
What this research studies
This research focuses on the development of new drugs and vaccines aimed at treating various types of cancer. It utilizes a structured approach that guides the process from initial discovery through to clinical application. The program emphasizes preclinical testing to evaluate the efficacy of these treatments and identifies biomarkers that can indicate their effectiveness. Patients may benefit from advancements in cancer therapies that arise from this comprehensive development program.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments and vaccines, improving patient outcomes.
How similar studies have gone: Previous research in preclinical drug development has shown promise in advancing cancer treatment options, indicating that this approach has potential for success.
Where this research is happening
-
University of Oklahoma Hlth Sciences Ctr
Oklahoma City, United States Active
Researchers
- Principal investigator: Rao, Chinthalapally V. — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Rao, Chinthalapally V.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.